Last reviewed · How we verify
NCT07255781: EMERGE
Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
trial testing Guselkumab Prefilled Syringe [Tremfya] in Psoriasis (PsO). Withdrawn.
30 November 2025
Quick facts
| Lead sponsor | University of California, San Diego |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 30 November 2025 |
| Primary completion | 30 November 2025 |
| Estimated completion | 30 November 2025 |
Drugs / interventions tested
- Guselkumab Prefilled Syringe [Tremfya] — full drug profile →
Conditions studied
- Psoriasis (PsO) — all drugs for Psoriasis (PsO) →
- PsA (Psoriatic Arthritis) — all drugs for PsA (Psoriatic Arthritis) →
- NAFLD (Nonalcoholic Fatty Liver Disease) — all drugs for NAFLD (Nonalcoholic Fatty Liver Disease) →
Sponsor
University of California, San Diego
Who can join
18 and older, any sex, with Psoriasis (PsO) or PsA (Psoriatic Arthritis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this research study is to better understand if there is an association between non-alcoholic fatty liver disease (NAFLD) and active psoriatic disease (PD), and to assess the effect of Guselkumab (a medication approved by the FDA instead of the standard of care to treat PD), for NAFLD patients who receive Guselkumab for their PD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07255781
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Psoriasis (PsO)
Currently open trials in the same condition.
- NCT07401992 — Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis · Phase 4 · recruiting
- NCT07370766 — Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada · recruiting
- NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting
- NCT07233291 — A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults · Phase 2 · recruiting
- NCT07169019 — Microbiome and Clinical Response to Probiotics and Methotrexate in Early Psoriasis: a Pilot Study · EARLY_PHASE1 · recruiting
Other University of California, San Diego trials
Trials by the same sponsor.
- NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
- NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
- NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
- NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07255781 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
- Last refreshed: 23 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07255781.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing